

New Drug Candidate for Methicillin-Resistant Staphylococcus Aureus Bacterial Infection and Other Drug Resistant Bacteria

Track Code: 2020-RAMA-68859

Categories:

- Chemistry and Chemical Analysis
- Pharmaceuticals

Keywords:

- Antibacterial
- Antibiotic
- Antibiotic Resistance
- Chemistry and Chemical Analysis
- Drug Development
- Pharmaceuticals

Researchers at Purdue University have developed new drug candidates to treat Methicillin-resistant Staphylococcus aureus (MRSA)-related bacterial infection. MRSA-related infections are reaching a level of critical concern according to the Centers for Disease Control and Prevention. Purdue researchers have synthesized a line of 187 potential drug candidates, several of which exhibit excellent antimicrobial activity. Through in vitro against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (VRE), or Streptococcus pneumoniae in a human skin cells infection model, the new drug candidates showed no signs of cytotoxicity, and the skin cells maintained viability between 65-100%. Purdue researchers optimized these new antibacterial drug candidates and achieved a minimum inhibitory concentration between 3.0-5.2 micromolar against different bacterial strains and eliminated 98-99% of bacteria in two hours whereas the current treatment, vancomycin, requires twelve hours.

Advantages

- Fast-Acting
- Effective Against Drug Resistant Bacterial Strains
- Safe in Mammalian Cells

Potential Applications

- Pharmaceutics
- Antibacterial Drug Development
- Antibiotics

Recent Publication:

"Beta-,gamma-Diaryl alpha-methylene-gamma-butyrolactones as potent antibacterials against methicillin-resistant Staphylococcus aureus"

Elsevier Journal of Bioorganic Chemistry

DOI: 10.1016/j.bioorg.2020.104183

People:

- Ramachandran, Padinjaremadhom V (Project leader)
- Seleem, Mohamed

Intellectual Property:

Application Date: April 9, 2020

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: otcip@prf.org